share_log

Sanofi's IMROZ Phase 3 Study Shows Sarclisa With VRd Reduces Risk Of Disease Progression Or Death By 40% In Newly Diagnosed Transplant-Ineligible Multiple Myeloma; First Global Phase 3 Study Of Anti-CD38 With VRd To Improve PFS And Show Deep...

Benzinga ·  Jun 4 04:21

Sanofi's IMROZ Phase 3 Study Shows Sarclisa With VRd Reduces Risk Of Disease Progression Or Death By 40% In Newly Diagnosed Transplant-Ineligible Multiple Myeloma; First Global Phase 3 Study Of Anti-CD38 With VRd To Improve PFS And Show Deep Responses; Results Presented At ASCO And Published In NEJM

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment